Ticker >

Jenburkt Pharma share price

Jenburkt Pharmaceuticals Ltd.

BSE: 524731 SECTOR: Pharmaceuticals & Drugs  14k   54   3

1087.15
+74.15 (7.32%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 1137.7

Today's Low

₹ 1024

52 Week High

₹ 1210

52 Week Low

₹ 586.9

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

479.79 Cr.

Enterprise Value

400.6 Cr.

No. of Shares

0.44 Cr.

P/E

17.12

P/B

3.15

Face Value

₹ 10

Div. Yield

1.41 %

Book Value (TTM)

₹  345.22

CASH

79.19 Cr.

DEBT

0 Cr.

Promoter Holding

46.71 %

EPS (TTM)

₹  63.5

Sales Growth

3.82%

ROE

19.43 %

ROCE

26.28%

Profit Growth

5.57 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Jenburkt Pharmaceuticals Ltd.

Zydol suspension Triben Zenglobin Zix Powergesic Nervijen Allerzine Glucotrol Pantazole La-Viril

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year3.82%
3 Year9.11%
5 Year2.97%

Profit Growth

1 Year5.57%
3 Year16.33%
5 Year5.58%

ROE%

1 Year19.43%
3 Year20.21%
5 Year19.6%

ROCE %

1 Year26.28%
3 Year26.66%
5 Year25.91%

Debt/Equity

0

Price to Cash Flow

59.06

Interest Cover Ratio

130.9922

CFO/PAT (5 Yr. Avg.)

0.661069412537709

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 46.71 0.00
Jun 2024 46.71 0.00
Mar 2024 47.23 0.00
Dec 2023 47.39 0.00
Sep 2023 47.42 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 16.3274746329556% for the Past 3 years.
  • The company has significantly decreased its debt by 2.4389 Cr.
  • Company has been maintaining healthy ROE of 20.2066391892844% over the past 3 years.
  • Company has been maintaining healthy ROCE of 26.6564527350378% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 130.9922.
  • The Company has been maintaining an effective average operating margins of 20.4562352796092% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -16.1976 days.
  • Company has a healthy liquidity position with current ratio of 6.6994.

 Limitations

  • The company has shown a poor revenue growth of 9.10949391064495% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 38.29 35.66 38.84 32.54 41.22
Total Expenditure 29.19 28.47 28.99 23.25 29.79
Operating Profit 9.1 7.19 9.85 9.29 11.43
Other Income 1.1 1.35 1.19 1.41 1.85
Interest 0.07 0.07 0.06 0.12 0.12
Depreciation 0.59 0.63 0.62 0.52 0.64
Exceptional Items 0 0 0 0 0
Profit Before Tax 9.54 7.84 10.37 10.06 12.52
Tax 2.22 2.44 2.48 2.65 2.92
Profit After Tax 7.32 5.4 7.88 7.42 9.6
Adjusted EPS (Rs) 16.59 12.24 17.86 16.8 21.76

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 118.89 109.29 123.98 136.75 141.97
Total Expenditure 99.15 89.45 96.73 106.38 108.85
Operating Profit 19.74 19.84 27.26 30.37 33.12
Other Income 4.22 4.31 4.95 5.12 4.67
Interest 0.53 0.47 0.43 0.37 0.27
Depreciation 2.3 2.04 1.9 2.26 2.34
Exceptional Items 0 0 0 0 0
Profit Before Tax 21.14 21.64 29.87 32.86 35.18
Tax 6.27 5.14 7.57 8.26 9.2
Net Profit 14.87 16.5 22.3 24.61 25.98
Adjusted EPS (Rs.) 32.4 35.96 48.58 55.76 58.86

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 4.59 4.59 4.59 4.41 4.41
Total Reserves 75.41 93.88 112.79 117.98 140.53
Borrowings 0 0 0 0 0
Other N/C liabilities 4.5 3.99 3.92 3.24 2.98
Current liabilities 19.89 17.99 21.28 15.76 16.38
Total Liabilities 104.39 120.45 142.58 141.39 164.3
Assets
Net Block 11.73 10.55 11.4 10.45 10.36
Capital WIP 0.12 0.38 0.21 0.96 1.24
Intangible WIP 0 0 0 0 0
Investments 2.5 6.5 7.96 11.18 16.79
Loans & Advances 0.29 0.32 11.49 11.55 25.36
Other N/C Assets 0.13 22.71 35.61 26.16 0.82
Current Assets 89.63 79.99 75.9 81.09 109.73
Total Assets 104.39 120.45 142.58 141.39 164.3
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 21.14 21.64 29.87 32.86 35.09
Adjustment -1.22 -1.6 -2.25 -1.54 -0.49
Changes in Assets & Liabilities 0.57 5.25 -10.79 -6.05 -18.22
Tax Paid -5.46 -5.84 -7.56 -8.22 -8.26
Operating Cash Flow 15.02 19.45 9.27 17.05 8.12
Investing Cash Flow -2.88 -18.78 -1.2 2.62 -0.58
Financing Cash Flow -10.83 -0.71 -5.53 -21.04 -7.08
Net Cash Flow 1.31 -0.04 2.54 -1.37 0.47

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 47.42 47.39 47.23 46.71 46.71
ashish uttam bhuta 5.92 5.92 5.92 5.92 5.92
bhavika ashish bhuta 1.17 1.17 1.17 1.17 1.17
bhuta holdings private li... 13.96 13.96 13.96 13.96 13.96
jagruti ketan bhuta 0.67 0.65 0.63 0.63 0.63
jayshree uttam bhuta 12.16 12.16 12.16 12.16 12.16
kalindi hemendra bhuta 9.06 9.06 9.06 9.06 9.06
kunti ketan gala 1.16 1.16 1.16 1.16 1.16
mahesh harshad bhuta - - - 1.54 1.54
riddhi haresh shroff 0.73 0.73 0.73 0.73 0.73
shivani haresh shroff 0.39 0.39 0.39 0.39 0.39
mahesh h bhuta 1.55 1.54 1.54 - -
prakash h bhuta 0.67 0.67 0.52 - -
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 52.58 52.61 52.77 53.29 53.29
bharath c jain 1.02 1.02 1.02 1.02 1.02
investor education and pr... - - - - 2.06
kaushik daga 1.02 1.02 1.02 1.02 1.02
nirmala vinodkumar daga 3.30 3.30 3.30 3.30 3.30
parshva kumar daga 1.05 1.05 1.05 1.05 1.05
rajiv garg 1.18 1.18 1.18 1.18 1.18
ranjeet singh sibia 1.40 1.49 1.49 1.49 1.49
sushila paraskumar daga 1.05 1.05 1.05 1.05 1.05
varun daga 1.03 1.03 1.03 1.03 1.03
investor education and pr... 2.07 2.07 2.07 2.06 -
optirational ventures llp... 1.09 1.20 1.14 1.12 -
fidelity northstar fund 1.38 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Jenburkt Pharmaceuticals informs about board meeting28 Oct 2024, 2:26PM Jenburkt Pharmaceuticals informs about loss of share certificate30 Jul 2024, 12:49PM Jenburkt Pharmaceuticals informs about newspaper clippings27 Jul 2024, 2:57PM Jenburkt Pharma - Quaterly Results26 Jul 2024, 3:05PM Jenburkt Pharma - Quaterly Results26 Jul 2024, 3:05PM Jenburkt Pharma - Quaterly Results26 Jul 2024, 3:05PM Jenburkt Pharma - Quaterly Results28 May 2024, 5:57PM Jenburkt Pharmaceuticals informs about issuance of letter of confirmation2 Mar 2024, 2:34PM Jenburkt Pharma - Quaterly Results6 Feb 2024, 4:29PM Jenburkt Pharma - Quaterly Results6 Feb 2024, 4:29PM Jenburkt Pharma - Quaterly Results6 Feb 2024, 4:29PM Jenburkt Pharmaceuticals informs about loss of share certificate13 Dec 2023, 5:16PM Jenburkt Pharma - Quaterly Results7 Nov 2023, 4:41PM Jenburkt Pharma - Quaterly Results7 Nov 2023, 4:41PM Jenburkt Pharmaceuticals informs about loss of share certificate9 Aug 2023, 2:18PM Jenburkt Pharma - Quaterly Results8 Aug 2023, 5:04PM Jenburkt Pharma - Quaterly Results8 Aug 2023, 5:04PM Jenburkt Pharma - Quaterly Results8 Aug 2023, 5:04PM Jenburkt Pharmaceuticals informs about loss of share certificate14 Jul 2023, 4:44PM Jenburkt Pharmaceuticals informs about loss of share certificates7 Jul 2023, 2:18PM Jenburkt Pharma - Quaterly Results23 May 2023, 5:19PM Jenburkt Pharma - Quaterly Results23 May 2023, 5:19PM Jenburkt Pharma - Quaterly Results23 May 2023, 5:19PM Jenburkt Pharmaceuticals informs about board meeting 12 May 2023, 4:59PM Jenburkt Pharmaceuticals informs about disclosure14 Mar 2023, 12:55PM Jenburkt Pharmaceuticals informs about disclosure2 Mar 2023, 5:08PM Jenburkt Pharmaceuticals informs about newspaper publication 8 Feb 2023, 1:15PM Jenburkt Pharma - Quaterly Results7 Feb 2023, 5:26PM Jenburkt Pharma - Quaterly Results7 Feb 2023, 5:26PM Jenburkt Pharma - Quaterly Results7 Feb 2023, 5:26PM Jenburkt Pharmaceuticals submits daily report 12 Jan 2023, 5:33PM Jenburkt Pharmaceuticals informs about disclosure 22 Dec 2022, 10:37AM Jenburkt Pharmaceuticals informs about outcome of board meeting1 Dec 2022, 4:16PM Jenburkt Pharma - Quaterly Results8 Nov 2022, 3:47PM Jenburkt Pharma - Quaterly Results8 Nov 2022, 3:47PM Jenburkt Pharma - Quaterly Results8 Nov 2022, 3:47PM Jenburkt Pharma - Quaterly Results1 Aug 2022, 4:04PM Jenburkt Pharma - Quaterly Results1 Aug 2022, 4:04PM Jenburkt Pharma - Quaterly Results1 Aug 2022, 4:04PM Jenburkt Pharmaceuticals informs about compliances-certificate 8 Jul 2022, 2:21PM Jenburkt Pharmaceuticals informs about newspaper publication 28 May 2022, 12:14PM Jenburkt Pharmaceuticals informs about board meeting intimation 16 May 2022, 3:56PM Jenburkt Pharmaceuticals’ premium consumer-wellness division launches ‘Zixa Strong’ 4 Apr 2022, 10:29AM Jenburkt Pharmaceuticals informs about press release2 Apr 2022, 10:21AM Jenburkt Pharmaceuticals informs about trading window closure23 Mar 2022, 2:21PM Jenburkt Pharma - Quaterly Results12 Feb 2022, 12:41PM Jenburkt Pharmaceuticals informs about closure of trading window28 Sep 2021, 4:34PM Jenburkt Pharmaceuticals informs about newspaper publications4 Jun 2021, 11:44AM Jenburkt Pharmaceuticals informs about newspaper publication27 May 2021, 2:16PM Jenburkt Pharmaceuticals informs about board meeting24 May 2021, 3:57PM

Jenburkt Pharma Stock Price Analysis and Quick Research Report. Is Jenburkt Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Jenburkt Pharma and its performance over the period of time. Jenburkt Pharma stock price today is Rs 1087.15.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Jenburkt Pharma cash from the operating activity was Rs 8.1238 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Jenburkt Pharma has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Jenburkt Pharma , the EPS growth was 5.5687 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Jenburkt Pharma has OPM of 23.3288839268419 % which is a good sign for profitability.
     
  • ROE: Jenburkt Pharma have a average ROE of 19.4346 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Jenburkt Pharma is Rs 1087.15. One can use valuation calculators of ticker to know if Jenburkt Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Jenburkt Pharma
X